CONCORDBIO Q2 FY27 Earnings Call: Guides FY27 Growth Above 18%, Sees Margins Reverting To 38-40%

CONCORDBIO held its Q2 FY27 earnings call on October 27, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Double-Digit Growth Across Products and Geographies

• Q2 FY27 revenue of Rs.309.1 crore, +25% YoY (vs Rs.247.1 crore in Q2 FY26); H1 FY27 revenue of Rs.566.6 crore, +26% YoY (vs Rs.451.1 crore in H1 FY26), with growth from every product category and every geography.
• Q2 FY27 EBITDA of Rs.104.4 crore (+18% YoY) at 33.8% margin; H1 FY27 EBITDA of Rs.187 crore (+25% YoY) at 33.0% vs 33.2% in H1 FY26. Excluding Stelon and injectables facility expenses (revenues yet to scale), EBITDA margin would have been 37.1% in Q2 and ~37.8% in H1 FY27.
• Q2 FY27 PAT of Rs.69.6 crore, +10.3% YoY; H1 FY27 PAT of Rs.127.3 crore, +19% YoY, at a 22.5% PAT margin for both periods. Excluding JV profit share, H1 FY27 PAT grew 23% YoY (vs Rs.103.2 crore in H1 FY26).
• Q2 FY27 gross margin of 76.2%, contracting ~400bps YoY on higher raw material (particularly solvents) prices and API product-mix changes; H1 FY27 gross margin of 77.4% vs 79.1% in H1 FY26 — relatively stable on a half-yearly basis.
• API revenue of Rs.250.1 crore (+30% YoY) vs formulation revenue of Rs.58.9 crore (+6% YoY) in Q2 FY27; management reiterated the overall business growth is the better evaluation lens, as customer procurement strategies influence the split.
• Oncology nearly doubled (~2x) YoY in Q2/H1 FY27; immunosuppressants delivered high double-digit growth; anti-infectives and antifungal grew in line with the company average.
• Domestic API revenue +42% YoY in Q2 FY27; exports +8% — management noted that including deemed exports (customers shifting procurement to Indian subsidiaries for subsequent export), the export contribution would be significantly higher.

FY27 Guidance Reaffirmed Above Historical Trend

• FY 2026-2027 revenue growth guided "slightly better" than the historical ~18%, with H1 FY27 top line already up 26% and management citing fair visibility on Q3 FY27 numbers.
• FY 2025-2026 degrowth framed as non-structural — management attributed it to a "global phenomena effect"; excluding FY 2025-2026, Concord grew 18-19% over the 3-, 5- and 25-year periods. Work done in FY 2025-2026 that did not fructify due to customer risk aversion is fructifying in FY 2026-2027.
• Management did not commit to a specific FY 2027-2028 growth number when asked whether 18-20%+ resumes, citing the 18-19% historical CAGR and positioning over the next 2-3 years (FY 2027-2028 onward) to take significant market share via product mix, capacities, and a pipeline of products "nobody in India is developing," against competition from Europe/Southeast Asia.
• API business growth of 18-19% over the next 2-3 years (FY 2027-2028 to FY 2029-2030) was framed by management as a "safe" assumption, with injectables, CDMO, and finished formulations expected to drive growth beyond that historical rate.
• Effective tax rate guided at 24-25% for the remainder of FY 2026-2027 and for FY 2027-2028 by CEO Ankur Vaid; no elevation like Q1-Q2 FY 2026-2027 is expected going forward.
• Immunosuppressant market growth of ~10% (period unspecified) was cited by management, with second-source conversions the bigger growth contributor and Latin America opening up following ANVISA inspections, whose impact plays out 4-5 months after the inspection.

Input-Cost Drag Viewed as Temporary; Path Back to 38-40%

• Gross margin contracted ~400bps YoY in FY 2026-2027 on higher raw material — particularly solvents — prices amid geopolitical uncertainties and supply chain disruptions, plus higher power and fuel costs, partly offset by renewable energy investments made in FY 2026-2027.
• Management expects to recover the margin impact on a full-year FY 2026-2027 basis through revenue improvement, cost optimization, and inventory management, and views the pressures as temporary; no raw material pass-through to customers is planned — management called pass-through "quite challenging" and would consider it only if cost increases became a long-term issue.
• Margin path from 33-34% to 38-39% (period unspecified, tied to ramp-up) per management, driven by positive Stelon contribution and injectables ramp-up; the analyst referenced management's prior guidance of reverting to 40% reported margins in FY 2027-2028. Per the Q2 FY27 presentation, EBITDA margin excluding Stelon/injectables drag is ~38%, with a return to the historical 38-40% range expected over the next few years (FY 2027-2028 onward) as Stelon, injectables and Unit 3 Limbasi ramp up.
• Fermentation-based process limits cost exposure — most raw materials are agro-based, with only the solvent/power-linked portion affected by the fuel price and operating cost inflation of the last 6-8 months.
• API-to-formulation split of ~78:22 in Q2 FY27 and ~80:20 in H1 FY27, broadly in line with the historical 80:20 mix around which capacities are designed; management expects gross margins to revert to historical levels as input conditions improve (timeline unspecified) and advises tracking EBITDA rather than gross margins, since API transfers to formulation units at market price can distort gross margins at low utilization.

Growth Investments Still Nascent; Ramps Expected from H2 FY27

• Stelon (US subsidiary) revenue contributions expected from H2 FY 2026-2027 — materials and finished products have been supplied to the US, with traction starting and contribution turning positive as sales ramp; tofacitinib already supplied, MMF oral suspension supply expected in Q3 FY 2026-2027. Formulation transition from Advagen to Stelon weighed on Q2 formulation growth (+6%).
• Injectable contracts expected to materialize in H2 FY 2026-2027 — several potential customers audited/inspected the facility in Q2 FY27; CEO Ankur Vaid sized the injectables TAM at ~Rs.5,000 crore (period unspecified) and said the company has built in ~Rs.300 crore of top line over the next 3 to 4 years (through roughly FY 2029-2030/FY 2030-2031), termed achievable if these customers come on board.
• Unit 4 (injectables) utilization at only ~5% and Unit 2 (oral solids) at 21% in Q2 FY27 (per CFO Raviraj Karia); Unit 1 at 75% and Unit 3 at 55%. Utilization is expected to rise with Stelon and new ANDA approvals (period unspecified).
• Inspira dermatology division targets a ~Rs.5,000 crore India TAM (period unspecified) per CEO Ankur Vaid, who stated Concord is the only company in India fully integrated from API to finished formulation; scaling to ~Rs.400-500 crore of revenue is expected to take at least 4 to 5 years from launch (~Q2 FY 2026-2027, i.e., no earlier than ~FY 2030-31).
• CDMO currently contributes ~$2 million annually from a single commercial project (Concord classifies as CDMO only where IPR rests with the third-party innovator); the opportunity in discussion with the customer — which launched its NCE in the US ~1.5 years ago and sees the opportunity as potentially much larger — is around the $2 million mark (period unspecified), with Concord as the customer's exclusive manufacturer. Management does not give CDMO-specific guidance.

Product Catalysts Building Across US and Emerging Markets

• H1 FY27 regulatory milestones — ANDA approvals for tofacitinib and mycophenolate mofetil oral suspension; US DMF filed for fidaxomicin; USFDA inspection of the Unit 2 formulation facility at Valthera, Ahmedabad successfully completed; ANVISA approval received for the Unit 3 facility at Limbasi.
• Nystatin (commercialized ~1.5 years ago, FY 2025-2026) is gaining traction — several US customers have qualified Concord as a source and received validation quantities, with commercial supplies yet to begin; management expects a significant jump once commercial supplies start (period unspecified). Fusidic acid commercialization in emerging markets is expected around Q3 FY 2026-2027 before extending globally.
• Portfolio of 30+ commercial fermentation-based API products with another 10-15 in the pipeline; oncology traction from romidepsin (customers launching in the US) and everolimus, alongside core immunosuppressants (tacrolimus, MMF, mycophenolate sodium, cyclosporin) and sirolimus/pimecrolimus.
• Discount-led customer acquisition continues in Q2 FY 2026-2027 — management stated there has been no pricing pressure on Concord; significant price discounts vs competitors (enabled by economies of scale, fermentation expertise, and productivity) support share gains while profitability is maintained in line with the API business.
• Shareholders approved the board-recommended 1:1 bonus issue, effective in the coming weeks; the Inspira launch and a CDMO exploration in fermentation-based APIs round out strategic initiatives.

Disciplined Investment Cycle with Ample Headroom

• Capex guided at Rs.50-60 crore in each of FY 2026-2027 and FY 2027-2028 (aggregating ~Rs.100-120 crore across the two years), plus recurring maintenance capex of Rs.20-30 crore per year, per CFO Raviraj Karia.
• Zero-debt balance sheet with cash and cash equivalents of ~Rs.445 crore as of September 30, 2026, reflecting continued focus on financial discipline.
• Significant capacity already built across the 30+ product portfolio, supporting management's stated positioning to capture market share over the next 2-3 years (FY 2027-2028 onward).
• Key watch items: input-cost persistence (solvents, power/fuel), pace of Stelon and injectables ramp against low current utilization, and the gap between reported margins (33-34%) and the historical 38-40% range.